검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Lazertinib (Lazertinib) Janssen Research & Development, LL…·Carcinoma, Non-Small-Cell Lung ORR 76%·t½ 3.7 h |
|---|---|
Overview Program | Lazertinib |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | ANTIBODY |
Overview Target | Carcinoma, Non-Small-Cell Lung |
Overview Indication | Carcinoma, Non-Small-Cell Lung |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targeted therapy directed against epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition pathway |
MoA Biomarker | EGFR and ALK Positive |
PK/PD Half-life | 3.7 h |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | Class-level DILI saturation and hERG-driven risk stratification among 2024-2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis.. Newly approved kinase inhibitors (2024-2025) have limited post-approval safety data. We developed a weighted ToxPi framework to prioritize multi-endpoint liabilities spanning hERG cardiotoxicity, DILI, Ames genotoxicity, and CYP3A4-mediated d… |
Clinical Primary efficacy | ORR 76% |
Clinical ORR | 76.0% |
Clinical PFS | 20.6 |
Clinical OS | 49 |
Clinical Result source | ClinicalTrials.gov NCT04248829 |
Clinical Data Tier / Score | A · 76 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Lazertinib (Lazertinib) Janssen Research & Development, LL…·Carcinoma, Non-Small-Cell Lung ORR 76%·t½ 3.7 h |
|---|---|
Overview Program | Lazertinib |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | ANTIBODY |
Overview Target | Carcinoma, Non-Small-Cell Lung |
Overview Indication | Carcinoma, Non-Small-Cell Lung |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targeted therapy directed against epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition pathway |
MoA Biomarker | EGFR and ALK Positive |
PK/PD Half-life | 3.7 h |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | Class-level DILI saturation and hERG-driven risk stratification among 2024-2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis.. Newly approved kinase inhibitors (2024-2025) have limited post-approval safety data. We developed a weighted ToxPi framework to prioritize multi-endpoint liabilities spanning hERG cardiotoxicity, DILI, Ames genotoxicity, and CYP3A4-mediated d… |
Clinical Primary efficacy | ORR 76% |
Clinical ORR | 76.0% |
Clinical PFS | 20.6 |
Clinical OS | 49 |
Clinical Result source | ClinicalTrials.gov NCT04248829 |
Clinical Data Tier / Score | A · 76 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교